Nuvectis Pharma (NVCT) News Today $4.52 -0.17 (-3.62%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Marlio Charles Mosseri Purchases 17,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) StockDecember 17, 2024 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires $79,900.00 in StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri acquired 17,000 shares of the company's stock in a transaction on Friday, December 13th. The shares were purchased at an average cost of $4.70 per share, with a total value of $79,900.00. Following the completion of the purchase, the insider now directly owns 2,612,000 shares of the company's stock, valued at $12,276,400. This trade represents a 0.66 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.December 16, 2024 | marketbeat.comNuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors SymposiumDecember 10, 2024 | markets.businessinsider.comNuvectis Pharma Share Price (NVCT.US)November 19, 2024 | lse.co.ukNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 SharesNovember 19, 2024 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Buys $98,400.00 in StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur acquired 20,000 shares of Nuvectis Pharma stock in a transaction on Friday, November 15th. The shares were purchased at an average price of $4.92 per share, for a total transaction of $98,400.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,266,424 shares in the company, valued at $16,070,806.08. This trade represents a 0.62 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.November 18, 2024 | marketbeat.comNuvectis Pharma reports data from Phase 1b study of NXP800November 15, 2024 | finance.yahoo.comNuvectis Pharma Inc trading halted, volatility trading pauseNovember 15, 2024 | markets.businessinsider.comPositive Outlook for Nuvectis Pharma: Promising Clinical and Preclinical Developments Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comNuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer StudyNovember 14, 2024 | marketwatch.comNuvectis sinks after early-stage data for ovarian cancer therapyNovember 14, 2024 | seekingalpha.comNuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead DrugNovember 14, 2024 | benzinga.comNuvectis Pharma Reports Improved Q3 Financials and Clinical ProgressNovember 7, 2024 | markets.businessinsider.comNuvectis Pharma FY2024 EPS Estimate Boosted by Roth CapitalNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Stock analysts at Roth Capital increased their FY2024 EPS estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff now expects that the company will earn ($1.00)November 7, 2024 | marketbeat.comRoth Capital Predicts Nuvectis Pharma Q1 EarningsNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities research analysts at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for Nuvectis Pharma in a research note issued on Tuesday, November 5th. Roth Capital analyst J. Aschoff forecasts that the company will post earniNovember 6, 2024 | marketbeat.comNuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 5, 2024 | globenewswire.comNuvectis Pharma (NVCT) Gets a Buy from Roth MKMOctober 29, 2024 | markets.businessinsider.comNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer TherapeuticsOctober 24, 2024 | finance.yahoo.comNuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 7, 2024 | finance.yahoo.comNuvectis Pharma (NASDAQ:NVCT) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York CityOctober 2, 2024 | markets.businessinsider.comPESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to WatchSeptember 16, 2024 | finance.yahoo.comNuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5%Nuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5%September 11, 2024 | marketbeat.comNuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comNuvectis Shares Rally After Ovarian Cancer Drug Gets FDA's Orphan Drug DesignationAugust 29, 2024 | marketwatch.comNuvectis's NXP800 Granted FDA Orphan Drug Designation For ARID1a-Deficient Ovarian CancersAugust 29, 2024 | markets.businessinsider.comNuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal CancersAugust 29, 2024 | globenewswire.comPositive Signs As Multiple Insiders Buy Nuvectis Pharma StockAugust 28, 2024 | finance.yahoo.comQ3 2024 EPS Estimates for Nuvectis Pharma, Inc. Increased by HC Wainwright (NASDAQ:NVCT)Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Stock analysts at HC Wainwright boosted their Q3 2024 earnings per share estimates for shares of Nuvectis Pharma in a research note issued to investors on Tuesday, August 6th. HC Wainwright analyst J. Pantginis now expects that the company willAugust 9, 2024 | marketbeat.comNuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 6, 2024 | globenewswire.comNuvectis Pharma (NASDAQ: NVCT): 5 Reasons to Keep this Pharma Disruptor on Your RadarAugust 2, 2024 | msn.com5 Reasons Why Nuvectis Pharma (NASDAQ: NVCT) Is a Biopharma Innovator to WatchAugust 1, 2024 | msn.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest UpdateNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) was the recipient of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 884,200 shares, a decrease of 18.1% from the June 30th total of 1,080,000 shares. Approximately 12.0% of the shares of the company are short sold. Based on an average trading volume of 96,000 shares, the days-to-cover ratio is presently 9.2 days.July 28, 2024 | marketbeat.comInsiders hold 65% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recentlyJuly 28, 2024 | finance.yahoo.comNuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine MarketJuly 19, 2024 | theglobeandmail.com7 Penny Biotech Stocks to Triple Your InvestmentMay 28, 2024 | investorplace.comThe Veteran Pharma Founders That Keep Buying Their Own NASDAQ StockMay 20, 2024 | entrepreneur.comNuvectis Pharma: An Interesting Early Pipeline Does Not Justify A BuyMay 16, 2024 | seekingalpha.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires $13,075.60 in StockMay 16, 2024 | insidertrades.comNuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 16, 2024 | globenewswire.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases 1,940 Shares of StockNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur purchased 1,940 shares of the firm's stock in a transaction that occurred on Tuesday, May 14th. The stock was acquired at an average price of $6.74 per share, for a total transaction of $13,075.60. Following the completion of the purchase, the chief executive officer now owns 3,246,424 shares of the company's stock, valued at $21,880,897.76. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.May 15, 2024 | marketbeat.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires 2,000 Shares of StockMay 14, 2024 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Acquires 2,000 SharesNuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur acquired 2,000 shares of the business's stock in a transaction that occurred on Friday, May 10th. The stock was purchased at an average price of $6.40 per share, for a total transaction of $12,800.00. Following the acquisition, the chief executive officer now directly owns 3,244,484 shares in the company, valued at approximately $20,764,697.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 13, 2024 | marketbeat.comNuvectis Pharma, Inc. Expected to Post Q2 2024 Earnings of ($0.23) Per Share (NASDAQ:NVCT)Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Analysts at Roth Capital increased their Q2 2024 EPS estimates for shares of Nuvectis Pharma in a research report issued on Tuesday, May 7th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($0.23)May 10, 2024 | marketbeat.comFY2028 EPS Estimates for Nuvectis Pharma, Inc. (NASDAQ:NVCT) Boosted by Roth CapitalNuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at Roth Capital increased their FY2028 earnings estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, May 7th. Roth Capital analyst J. Aschoff now anticipates that the company will postMay 9, 2024 | marketbeat.comStrong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug TrialsMay 8, 2024 | markets.businessinsider.comNuvectis Pharma (NASDAQ:NVCT) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $21.00 price objective on shares of Nuvectis Pharma in a report on Wednesday.May 8, 2024 | marketbeat.comNuvectis Pharma Inc Reports Q1 2024 Financial OutcomesMay 8, 2024 | finance.yahoo.comNVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024May 7, 2024 | investorplace.comIs Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?April 17, 2024 | finance.yahoo.com Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. NVCT Media Mentions By Week NVCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCT News Sentiment▼1.940.60▲Average Medical News Sentiment NVCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCT Articles This Week▼31▲NVCT Articles Average Week Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PROC News NGNE News VYGR News DSGN News BTMD News CTNM News SLRN News KMDA News TRVI News CGC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
